Search
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: Serotonin (5-HT) 1F Receptor AgonistsVincristine
go.drugbank.com/drugs/DB00541ApprovedInvestigationalbecause of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). … It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar.
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: SULFATO DE VINCRISTINA 1 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE.Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigationalGanaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors.
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive ModulatorRescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846]. … Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIt acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345].
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalThe American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary … Argatroban is a direct, selective thrombin inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index